TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23237127

Group type: EXPERIMENTAL
Intervention: Expectation manipulation intervention during the 2 weeks before surgery
Number of subjects: 180

Group type: COMPARATOR
Intervention: Standard medical care (SMC) alone
Number of subjects: 180

Group type: COMPARATOR
Intervention: Attention-control group (supportive therapy)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Expectation manipulation intervention
Number of subjects: 180
Study: 21605672

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (28,000 IU/week)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 19104825

Group type: EXPERIMENTAL
Intervention: White test (WT)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (no bile leakage test)
Number of subjects: 137
Study: 18390492

Group type: EXPERIMENTAL
Intervention: HR intervention group
Number of subjects: 508

Group type: COMPARATOR
Intervention: HR control group
Number of subjects: 508

Group type: COMPARATOR
Intervention: LR control group
Number of subjects: 508
Study: 15516290

Group type: EXPERIMENTAL
Intervention: 25 microg/h F transdermal patches (N = 142)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: 50 microg/h F transdermal patches (N = 184)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: 75 microg/h F transdermal patches (N = 85)
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: 100 microg/h F transdermal patches (N = 135)
Number of subjects: 546
Study: 11303191

Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Number of subjects: 617

Group type: COMPARATOR
Intervention: Standard counseling regarding sexually transmitted disease
Number of subjects: 617
Study: 9722255

Group type: EXPERIMENTAL
Intervention: Systemic dexamethasone for 3 d followed by nebulized budesonide for 18 d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Systemic and inhaled saline
Number of subjects: 60
Study: 7979565

Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation including 0.8 mg folic acid
Number of subjects: 5502

Group type: EXPERIMENTAL
Intervention: Periconceptional multivitamin supplementation
Number of subjects: 5502
Study: 3058630

Group type: EXPERIMENTAL
Intervention: Single dose of steroids (32 mg of oral methylprednisolone, approximately 2 hours before CM challenge)
Number of subjects: 6763

Group type: EXPERIMENTAL
Intervention: Double dose of steroids (32 mg approximately 12 hours and 2 hours before CM challenge)
Number of subjects: 6763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6763
Study: 4939601

Group type: EXPERIMENTAL
Intervention: Nitrimidazine (Naxogin)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Metronidazole (Flagyl)
Number of subjects: 57
Study: 30316671

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery (Cystectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prophylactic treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hormonotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renal carcinomas
Number of subjects: 0
Study: 29401355

Group type: EXPERIMENTAL
Intervention: Animal-Assisted Therapy (AAT)
Number of subjects: 0
Study: 27401657

Group type: EXPERIMENTAL
Intervention: Co-implantation of a preloaded capsular tension ring (CTR) and aberration-free monofocal intraocular lens (IOL)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Monofocal intraocular lens (IOL) only
Number of subjects: 52
Study: 25209072

Group type: EXPERIMENTAL
Intervention: B'More Healthy Communities for Kids (BHCK) intervention
Number of subjects: 0
Study: 22124795

Group type: EXPERIMENTAL
Intervention: 8 mg Cu/d (supplemented group, SG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (placebo group, PG)
Number of subjects: 0
Study: 19561530

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: mesalazine scheduled daily
Number of subjects: 818

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 818
Study: 17957730

Group type: EXPERIMENTAL
Intervention: TENS with strong but comfortable non-painful stimulation
Number of subjects: 66

Group type: COMPARATOR
Intervention: TENS with sensory threshold stimulation
Number of subjects: 66
Study: 15922284

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 53
Study: 12192167

Group type: EXPERIMENTAL
Intervention: DTPa-HepB combination vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monovalent HepB vaccine
Number of subjects: 0
Study: 9655370

Group type: EXPERIMENTAL
Intervention: DHA group (7 subjects) - 6 g DHA/d for 90 days after a basal diet for 30 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (4 subjects) - stabilization or basal diet throughout the study
Number of subjects: 11
Study: 8075614

Group type: COMPARATOR
Intervention: Pulmicort
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 2592587

Group type: EXPERIMENTAL
Intervention: Velnacrine (100 mg) administered after an overnight fast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Velnacrine (100 mg) administered 15 minutes after a standard breakfast
Number of subjects: 24
Study: 5002114

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no exercise-induced asthma)
Number of subjects: 50
Study: 31418414

Group type: EXPERIMENTAL
Intervention: Logistic regression model based on age, Child‐Pugh classification, and fibrinogen
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Validation of the prediction model
Number of subjects: 262
Study: 29247110

Group type: EXPERIMENTAL
Intervention: eDCT
Number of subjects: 1354

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 1354
Study: 26323681

Group type: EXPERIMENTAL
Intervention: 88% phenol
Number of subjects: 49

Group type: COMPARATOR
Intervention: 10% sodium hydroxide
Number of subjects: 49
Study: 25041495

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 67
Study: 22936319

Group type: EXPERIMENTAL
Intervention: Synchronized therapy group (I-125 seeds implantation combined with chemotherapy and Chinese medicine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chemotherapy plus CM-treated group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chemotherapy-treated group
Number of subjects: 90
Study: 18926641

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 55

Group type: COMPARATOR
Intervention: Monoamine reuptake inhibitors
Number of subjects: 55

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 55
Study: 17632217

Group type: EXPERIMENTAL
Intervention: Quetiapine, 400 mg/d at bedtime
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 14767152

Group type: EXPERIMENTAL
Intervention: Multimodal cognitive-behavioral therapy (CBT)
Number of subjects: 42
Study: 11396366

Group type: EXPERIMENTAL
Intervention: CEF (cyclophosphamide, epirubicin, fluorouracil)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC‐>T (doxorubicin, cyclophosphamide, followed by paclitaxel)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dose-dense, dose-intense EC‐>T (epirubicin, cyclophosphamide, followed by paclitaxel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous regimens (CEF, FEC 100, CAF, AC‐>T)
Number of subjects: 0
Study: 9432099

Group type: EXPERIMENTAL
Intervention: Group A (1 training task once a week for 5 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Group B (2 training tasks per week for 2 weeks, then 3 tasks per week for 3 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Group C (control group, no additional eccentric exercise)
Number of subjects: 30
Study: 8234907

Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg t.i.d.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2826098

Group type: EXPERIMENTAL
Intervention: Cereal of whole-meal (diabetic diet)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Raw wheat whole-meal preparation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Heated wheat and corn whole-meal preparations
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Raw corn (oat) variant
Number of subjects: 19
Study: 31915255

Group type: EXPERIMENTAL
Intervention: Tiagabine (oral, 10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30268096

Group type: EXPERIMENTAL
Intervention: GEMS (Gait Enhancing Mechatronic System)
Number of subjects: 15

Group type: COMPARATOR
Intervention: NoGEMS (free ascending stairs)
Number of subjects: 15
Study: 28348720

Group type: EXPERIMENTAL
Intervention: EMDR therapy carried out by a psychologist
Number of subjects: 170

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: EMDR therapy
Number of subjects: 170
Study: 25619445

Group type: EXPERIMENTAL
Intervention: Patient referral alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Provider referral
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contract referral
Number of subjects: 0
Study: 23903476

Group type: EXPERIMENTAL
Intervention: Topical 0.03% budesonide rinse
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical 0.01% dexamethasone rinse
Number of subjects: 50
Study: 21098871

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily for 3 months
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (statin-free patients)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 92
Study: 18795985

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 3 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 6 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo CPAP for 3 weeks followed by therapeutic CPAP for 3 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP
Number of subjects: 52
Study: 17018819

Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 302

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 302
Study: 14725659

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 12
Study: 10885554

Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional open operations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-randomised studies
Number of subjects: 0
Study: 9478066

Group type: EXPERIMENTAL
Intervention: Cognitive impairment
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Paralysis
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Body weight reduction over 10 kg vs ideal weight
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Joint deformation
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Visual impairment
Number of subjects: 788
Study: 8334888

Group type: EXPERIMENTAL
Intervention: Triphasic combined oral contraceptive
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Low-dose monophasic combined oral contraceptive
Number of subjects: 1088
Study: 3090012

Group type: EXPERIMENTAL
Intervention: Exercise at sea level
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Breathing 100% O2 at altitude
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: O2 consumption exceeding 2.7 1/min at sea level
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Indexes of VA/Q dispersion
Number of subjects: 8
Study: 28103746

Group type: EXPERIMENTAL
Intervention: Human sender feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Human emotional feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Feedback processing
Number of subjects: 0
Study: 27305596

Group type: EXPERIMENTAL
Intervention: RF tissue reduction under local anesthesia with epinephrine
Number of subjects: 120

Group type: COMPARATOR
Intervention: RF tissue reduction under local anesthesia without epinephrine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison between group 1 and group 2
Number of subjects: 120
Study: 24621680

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg twice daily
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 1006
Study: 22430564

Group type: EXPERIMENTAL
Intervention: Image comparison method
Number of subjects: 126

Group type: COMPARATOR
Intervention: Adjacent prosthesis
Number of subjects: 126
Study: 20642691

Group type: EXPERIMENTAL
Intervention: EPO-beta (30,000 UI each) administered before surgery and at 12 h, 7 days, and 14 days posttransplantation.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no EPO-beta treatment).
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: EPO-beta group.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both groups.
Number of subjects: 104
Study: 17301056

Group type: EXPERIMENTAL
Intervention: Health education intervention (home-based physical exercise, dietary instructions, management aspects) for 15 months
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1135
Study: 15918388

Group type: EXPERIMENTAL
Intervention: i.v. remifentanil PCA (loading dose: 45 microg, maintenance dose: 1 microg min(‐1), bolus dose: 15 microg, lockout interval: 10 min)
Number of subjects: 69

Group type: COMPARATOR
Intervention: i.v. morphine PCA (loading dose: 5 mg, maintenance dose: 0.3 mg h(‐1), bolus dose: 1 mg, lockout interval: 15 min)
Number of subjects: 69
Study: 11448655

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg + sulfonylurea
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg + sulfonylurea
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo + sulfonylurea
Number of subjects: 560
Study: 9738729

Group type: EXPERIMENTAL
Intervention: 17% sucrose diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: 2% sucrose diet
Number of subjects: 9
Study: 7913852

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2691494

Group type: EXPERIMENTAL
Intervention: Conservative surgery (CS) with radiotherapy (RT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 0
Study: 7995695

Group type: EXPERIMENTAL
Intervention: Expanded polytetrafluoroethylene membrane
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no membrane)
Number of subjects: 38
Study: 465179

Group type: EXPERIMENTAL
Intervention: Cholestyramine plus usual treatment (rehydration, refeeding, furazolidone)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Usual treatment (rehydration, refeeding, furazolidone)
Number of subjects: 32
Study: 31009433

Group type: EXPERIMENTAL
Intervention: Cluster-set (CLUS, n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Traditional-set (TRAD, n = 10)
Number of subjects: 21
Study: 31093318

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 42
Study: 28809658

Group type: EXPERIMENTAL
Intervention: Cognitive-Functional (Cog-Fun) occupational therapy intervention
Number of subjects: 107

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 107
Study: 26437500

Group type: EXPERIMENTAL
Intervention: Refurbished resin composite restorations
Number of subjects: 26

Group type: COMPARATOR
Intervention: Untreated (negative control) restorations
Number of subjects: 26
Study: 24521630

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 28

Group type: COMPARATOR
Intervention: Gluten free diet, calcium and cholecalciferol (Control)
Number of subjects: 28
Study: 21247825

Group type: EXPERIMENTAL
Intervention: Pharmacist-focused health management program
Number of subjects: 130
Study: 19725969

Group type: EXPERIMENTAL
Intervention: Switching antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial antipsychotic therapy
Number of subjects: 0
Study: 17563126

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg plus paracetamol 500 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg
Number of subjects: 10
Study: 15068395

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: E298 allele
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: 4a allele
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: D/D298 homozygotes
Number of subjects: 760

Group type: EXPERIMENTAL
Intervention: ‐786T allele
Number of subjects: 760
Study: 11403726

Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9951580

Group type: EXPERIMENTAL
Intervention: Chemotherapy including doxorubicin and/or cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy without doxorubicin and/or cyclophosphamide
Number of subjects: 0
Study: 8091240

Group type: EXPERIMENTAL
Intervention: Single-agent cisplatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platinum-based multiagent chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxorubicin, ifosfamide, mitolactol, and vincristine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New platinum-based regimens
Number of subjects: 0
Study: 3292601

Group type: EXPERIMENTAL
Intervention: Superactivated charcoal (20 g twice daily)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Cholestyramine (8 g twice daily)
Number of subjects: 6
Study: 31845435

Group type: EXPERIMENTAL
Intervention: Bioactive cement
Number of subjects: 50

Group type: COMPARATOR
Intervention: Packable glass ionomer
Number of subjects: 50
Study: 30912806

Group type: EXPERIMENTAL
Intervention: Combined GH/GnRHa therapy
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Prepubertal status at onset of GH treatment
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 192
Study: 28830024

Group type: EXPERIMENTAL
Intervention: Cognitive exercise therapy (CET) in addition to cognitive-behavioral therapy (CBT) and graded exercise therapy (GET)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Cognitive exercise therapy (CET)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT) and graded exercise therapy (GET) alone
Number of subjects: 72
Study: 25638341

Group type: EXPERIMENTAL
Intervention: Individualized hormone adjustment (estrogen, progesterone, and luteinizing hormones)
Number of subjects: 171
Study: 24344178

Group type: EXPERIMENTAL
Intervention: Stressed participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study: 21522037

Group type: EXPERIMENTAL
Intervention: Motavizumab (15 mg/kg, five monthly doses)
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Palivizumab (15 mg/kg, five monthly doses)
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Motavizumab
Number of subjects: 1236

Group type: COMPARATOR
Intervention: Palivizumab
Number of subjects: 1236
Study: 19883270

Group type: EXPERIMENTAL
Intervention: 10 g lactulose
Number of subjects: 27

Group type: COMPARATOR
Intervention: 10 g glucose (placebo)
Number of subjects: 27
Study: 16534469

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 75

Group type: COMPARATOR
Intervention: Reference group (no therapy)
Number of subjects: 75
Study: 12813203

Group type: EXPERIMENTAL
Intervention: 99mTc-methylene diphosphonate (99mTc-MDP)
Number of subjects: 70
Study: 11571823

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03%
Number of subjects: 232

Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 232
Study: 9558860

Group type: EXPERIMENTAL
Intervention: Normothermia
Number of subjects: 32

Group type: COMPARATOR
Intervention: Hypothermia
Number of subjects: 32
Study: 7528560

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (2 million IU before CPB, 500,000 IU/h until end of operation, 2 million IU added to the prime) (N = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nontreated control group (N = 20)
Number of subjects: 40
Study: 2921600

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 50 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 100 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 200 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31863843

Group type: EXPERIMENTAL
Intervention: Sodium warnings
Number of subjects: 498
Study: 30986531

Group type: EXPERIMENTAL
Intervention: transcutaneous auricular VNS (tVNS)
Number of subjects: 58

Group type: COMPARATOR
Intervention: sham stimulation
Number of subjects: 58
Study: 28097332

Group type: COMPARATOR
Intervention: Postoperative incentive spirometry (IS)
Number of subjects: 224
Study: 25446610

Group type: EXPERIMENTAL
Intervention: RT with capecitabine (1200 mg/m²/d Monday‐Friday) plus irinotecan (50 mg/m²/wk × 4)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: RT with capecitabine (1650 mg/m²/d Monday‐Friday) plus oxaliplatin (50 mg/m²/wk × 5)
Number of subjects: 104
Study: 23691062

Group type: EXPERIMENTAL
Intervention: Anti-tuberculosis therapy (ATT) with corticosteroids for IRIS treatment
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Baseline plasma IL-6 and CRP levels
Number of subjects: 57
Study: 21856268

Group type: EXPERIMENTAL
Intervention: M‐NBI
Number of subjects: 353

Group type: COMPARATOR
Intervention: C‐WLI
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: M‐NBI with C‐WLI
Number of subjects: 353